Gala Therapeutics Receives FDA IDE Approval for a US Early Feasibility Study of Its RheOx™ System to Treat Chronic Bronchitis

MENLO PARK, Calif., July 12, 2018 /PRNewswire/ -- Gala Therapeutics (Gala) today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to conduct an Early Feasibility Study (EFS) to examine the......
. .
Veröffentlicht von: Finanzen.at - Nachrichten Ticker - 4 days ago

Share |